Predictive value of metastatic cervical lymph node ratio in papillary thyroid carcinoma recurrence

Head and Neck

Volumn 35, Issue 4, 2013, Pages 592-598

  Yip, Jonathan ^a   Orlov, Steven ^a   Orlov, David ^a   Vaisman, Alon ^a   Hernández, Karen Gõmez ^a   Etarsky, Daniel ^a   Kak, Ipshita ^a   Parvinnejad, Nikoo ^a   Freeman, Jeremy L ^b   Walfish, Paul G ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

clinical predictors; lymph nodes; nodal ratio; recurrence; thyroid carcinoma

Indexed keywords

ADULT; AGED; CANCER RECURRENCE; CANCER STAGING; CERVICAL LYMPH NODE; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPH NODE RATIO; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; THYROID CARCINOMA; THYROIDECTOMY;

ADULT; CARCINOMA, PAPILLARY; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECK DISSECTION; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; THYROID GLAND; THYROIDECTOMY;

EID: 84875382586     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23047     Document Type: Review

References (46)

1. Hall FT, Beasley NJ, Eski SJ, Witterick IJ, Walfish PG, Freeman JL,. Predictive value of serum thyroglobulin after surgery for thyroid carcinoma. Laryngoscope 2003; 113: 77-81.
2. DeGroot LJ, Kaplan EL, McCormick M, Straus FH,. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71: 414-424.
3. Greene FL, Page DL, Fleming ID, et al. American Cancer Society, American College of Surgeons, American Joint Committee on Cancer. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag; 2002.
4. Palme CE, Waseem A, Raza SN, Eski S, Walfish P, Freeman JL,. Management and outcome of recurrent well-differentiated thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2004; 130: 819-824.
5. Tubiana M, Schlumberger M, Rougier P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985; 55: 794-804.
6. Mazzaferri EL, Jhiang SM,. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428.
7. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
8. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
9. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS,. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114: 1050-1057; discussion 1057-1058.
10. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF,. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathological findings, therapy, and outcome. Mayo Clin Proc 1986; 61: 978-996.
11. Beasley NJ, Lee J, Eski S, Walfish P, Witterick I, Freeman JL,. Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg 2002; 128: 825-828.
12. Mazzaferri EL, Kloos RT,. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86: 1447-1463.
13. Orlov S, Orlov D, Shaytzag M, et al. Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Head Neck 2009; 31: 782-788.
14. Podnos YD, Smith D, Wagman LD, Ellenhorn JD,. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 2005; 71: 731-734.
15. Reddy RM, Grigsby PW, Moley JF, Hall BL,. Lymph node metastases in differentiated thyroid cancer under 2 cm. Surgery 2006; 140: 1050-1054; discussion 1054-1055.
16. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A,. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 2004; 135: 139-148.
17. Wada N, Duh QY, Sugino K, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 2003; 237: 399-407.
18. Yamashita H, Noguchi S, Murakami N, et al. Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer 1999; 86: 842-849.
19. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH,. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 2003; 98: 31-40.
20. Sugino K, Kure Y, Iwasaki H, et al. Metastases to the regional lymph nodes, lymph node recurrence, and distant metastases in nonadvanced papillary thyroid carcinoma. Surg Today 1995; 25: 324-328.
21. Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 2005; 90: 5723-5729.
22. Lang BH, Wong KP, Wan KY, Lo CY,. Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection. Ann Surg Oncol 2012; 19: 1257-1263.
23. Beal SH, Chen SL, Schneider PD, Martinez SR,. An evaluation of lymph node yield and lymph node ratio in well-differentiated thyroid carcinoma. Am Surg 2010; 76: 28-32.
24. Woodward WA, Vinh-Hung V, Ueno NT, et al. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol 2006; 24: 2910-2916.
25. Mammen JM, James LE, Molloy M, Williams A, Wray CJ, Sussman JJ,. The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry. Am J Surg 2007; 194: 349-354.
26. Hong KD, Lee SI, Moon HY,. Lymph node ratio as determined by the 7th edition of the American Joint Committee on Cancer staging system predicts survival in stage III colon cancer. J Surg Oncol 2011; 103: 406-410.
27. Mariette C, Piessen G, Briez N, Triboulet JP,. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008; 247: 365-371.
28. Bando E, Yonemura Y, Taniguchi K, Fushida S, Fujimura T, Miwa K,. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol 2002; 9: 775-784.
29. Inoue K, Nakane Y, Iiyama H, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 2002; 9: 27-34.
30. Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, Kamat AM,. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol 2006; 176: 53-57; discussion 57.
31. Leggett MD, Chen SL, Schneider PD, Martinez SR,. Prognostic value of lymph node yield and metastatic lymph node ratio in medullary thyroid carcinoma. Ann Surg Oncol 2008; 15: 2493-2499.
32. Shrime MG, Ma C, Gullane PJ, et al. Impact of nodal ratio on survival in squamous cell carcinoma of the oral cavity. Head Neck 2009; 31: 1129-1136.
33. Shrime MG, Bachar G, Lea J, et al. Nodal ratio as an independent predictor of survival in squamous cell carcinoma of the oral cavity. Head Neck 2009; 31: 1482-1488.
34. Vaisman A, Orlov S, Yip J, et al. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck 2010; 32: 689-698.
35. Golger A, Fridman TR, Eski S, Witterick IJ, Freeman JL, Walfish PG,. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma. J Endocrinol Invest 2003; 26: 1023-1031.
36. Toft A, Beckett G,. Use of recombinant thyrotropin. Lancet 2002; 359: 1874-1875.
37. Arora N, Turbendian HK, Scognamiglio T, et al. Extrathyroidal extension is not all equal: implications of macroscopic versus microscopic extent in papillary thyroid carcinoma. Surgery 2008; 144: 942-947; discussion 947-948.
38. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16: 1229-1242.
39. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002; 26: 879-885.
40. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC,. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89: 3668-3676.
41. Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008; 37: 457-480.
42. Lin JD,. Papillary thyroid carcinoma with lymph node metastases. Growth Factors 2007; 25: 41-49.
43. Park HJ, Kim JY, Park KY, Gong G, Hong SJ, Ahn IM,. Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas. Thyroid 2000; 10: 211-217.
44. Ebrahimi A, Clark JR, Zhang WJ, et al. Lymph node ratio as an independent prognostic factor in oral squamous cell carcinoma. Head Neck 2011; 33: 1245-1251.
45. Sippel RS, Chen H,. Controversies in the surgical management of newly diagnosed and recurrent/residual thyroid cancer. Thyroid 2009; 19: 1373-1380.
46. Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010; 20: 1341-1349.